The therapeutic potential of fatty acid binding protein 4 (FABP4) is widely acknowledged. Currently, there are numerous clinical studies that indicate how fatty acid binding protein 4 inhibitors could be useful in the treatment of various diseases. To identify new and more potent inhibitors, we utilized a two-step computational approach to design novel structures. Through the use of this approach, we were able to identify a new class of FABP4 inhibitors (FABP4i IC50 2.97 to 23.18 µM) that are capable of inhibiting the activity of the protein as low as Arachidonic acid (FABP4i IC50 3.42 ± 0.54 µM). In this communication, we present the detailed structural, biological evaluation as well as the sinthetic procedures of the new pyridazinone-based scaffold FABP4i.